OKYO Pharma Ltd ADR

Yahoo Finance • 17 days ago

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition as... Full story

Mentioned:

Yahoo Finance • 3 months ago

OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data

Investing.com - H.C. Wainwright has reiterated a Buy rating and $7.00 price target on OKYO Pharma Ltd. (NASDAQ:OKYO), representing a 136% upside from the current price of $2.96, following positive Phase 2 trial results for its neuropathic... Full story

Yahoo Finance • 3 months ago

OKYO Pharma reports results from Urcosimod trial

[Light beam is shining through retina and lens on eyesight exam] Zorica Nastasic/E+ via Getty Images * OKYO Pharma (NASDAQ:OKYO [https://seekingalpha.com/symbol/OKYO]) shared positive results from a recent mid-stage study that tested Ur... Full story

Yahoo Finance • 3 months ago

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment.U... Full story

Yahoo Finance • 8 months ago

OKYO Pharma Announces Chairman and CEO Acquire Shares

LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular co... Full story

Yahoo Finance • 2 years ago

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP.Second clinical indication for OK-101 wh... Full story

Yahoo Finance • 2 years ago

OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")

Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the entire 12-week trial.The dropout rate is... Full story

Yahoo Finance • 2 years ago

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today... Full story

Yahoo Finance • 2 years ago

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today... Full story

Yahoo Finance • 2 years ago

OKYO Pharma Limited Announces Withdrawal of Public Offering

Yahoo Finance • 2 years ago

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

Full enrollment achieved on September 6th with a total of 240 patients enrolled in studyTop-line data planned for release in December 2023Phase 2 trial is designed as a potential registration trial, with pre-specified primary efficacy endp... Full story

Yahoo Finance • 2 years ago

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

Full enrollment anticipated by first week of SeptemberOKYO on schedule to release top-line data before end of 2023Phase 2 trial is designed as potential registration trial with pre-specified primary efficacy endpoints covering both a sign... Full story

Yahoo Finance • 2 years ago

OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule

NEW YORK and LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address... Full story

Yahoo Finance • 2 years ago

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

LONDON and NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet n... Full story